top of page

ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF

John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than slowing down, the progression of this difficult to treat disease.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page